nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-206D05EB·Framework v5.8·Pipeline v0.4·Evaluated 18 Aug 2026·OECD: 3.2 Clinical medicine·Subfield: Molecular Biology·Basis: Full text·Type: Narrative review

The molecular biology and therapeutic potential of Nrf2 in leukemia

Atefeh Khodakarami et al.Atefeh Khodakarami, Sara Adibfar, Vahid Karpisheh et al.·2022·10.1186/s12935-022-02660-5 ↗

Primary claim

Nrf2 protects cancerous cells from apoptosis and increases proliferation, angiogenesis, and metastasis. It promotes resistance to chemotherapy and radiotherapy in various solid tumors and hematological malignancies

Supported · multiple preclinical leukemia studies support chemoresistance, but the narrative selection method and cross-cancer context limit certainty
In brief

A broad leukemia-focused Nrf2 synthesis that organizes preclinical evidence effectively, but one-sided selection leaves its therapeutic conclusions less secure.

ReliabilityCaveats4 of 4 checks completeRead the entry ↓
Abstract

NF-E2-related factor 2 (Nrf2) transcription factor has contradictory roles in cancer, which can act as a tumor suppressor or a proto-oncogene in different cell conditions (depending on the cell type and the conditions of the cell environment). Nrf2 pathway regulates several cellular processes, including signaling, energy metabolism, autophagy, inflammation, redox homeostasis, and antioxidant regulation. As a result, it plays a crucial role in cell survival. Conversely, Nrf2 protects cancerous cells from apoptosis and increases proliferation, angiogenesis, and metastasis. It promotes resistance to chemotherapy and radiotherapy in various solid tumors and hematological malignancies, so we want to elucidate the role of Nrf2 in cancer and the positive point of its targeting. Also, in the past few years, many studies have shown that Nrf2 protects cancer cells, especially leukemic cells, from the effects of chemotherapeutic drugs. The present paper summarizes these studies to scrutinize whether targeting Nrf2 combined with chemotherapy would be a therapeutic approach for leukemia treatment. Also, we discussed how Nrf2 and NF-κB work together to control the cellular redox pathway. The role of these two factors in inflammation (antagonistic) and leukemia (synergistic) is also summarized.

Key Claims

Primary finding · Supported

Nrf2 protects cancerous cells from apoptosis and increases proliferation, angiogenesis, and metastasis. It promotes resistance to chemotherapy and radiotherapy in various solid tumors and hematological malignancies

multiple preclinical leukemia studies support chemoresistance, but the narrative selection method and cross-cancer context limit certainty

Abstract
Quote verified
Secondary · Supported

Nrf2 and NF-κB work together to control the cellular redox pathway; antagonistic in inflammation, synergistic in leukemia

cited mechanistic studies support pathway interaction, though the unsystematic narrative synthesis limits confidence in its generality

Abstract; Nrf2 and inflammation subsection
Secondary · Unsupported

Nrf2 is a poor prognostic marker in leukemia

the review does not present commensurate clinical prognostic evidence in leukemia

Conclusion
Quote verified
Secondary · Tentative

Inhibition of Nrf2, whether by knockdown techniques, siRNA, or the use of inhibitory compounds, combined with current frontline therapies, stops cell growth and causes apoptosis in malignant cells

individual preclinical studies support growth inhibition and apoptosis, but broad generalization beyond tested models remains uncertain

Conclusion
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Broad leukemia subtype evidence map

Table 1 consolidates findings across CML, AML, APL, CLL, and ALL, including study type, experimental model, intervention, and reported result.

↳ Table 1, pages 13–14

#contribution

Useful pathway interaction framework

The manuscript uses Nrf2–NF-κB interactions to connect redox regulation, inflammation, leukemia progression, and treatment resistance.

↳ Nrf2 and inflammation subsection; Figures 2 and 4

#reporting

Logical molecular-to-disease organization

The review proceeds from Nrf2 structure and regulation through biological functions and then leukemia-specific evidence, making a long technical discussion navigable.

↳ Nrf2 structure through leukemia subtype sections

Limitations

#methodological rigour

Conflicting evidence receives little analysis

The AML section acknowledges studies in which Nrf2 activation may be beneficial but does not compare their mechanisms or implications with the dominant inhibition narrative.

↳ Nrf2 and Acute myeloid leukemia subsection, page 16

#methodological rigour

No literature selection method reported

No databases, search dates, search terms, or inclusion criteria are reported, leaving the completeness and balance of the literature selection uncertain.

↳ Entire manuscript; no review methods section

#reporting

Conclusions outrun preclinical evidence base

The Conclusion labels Nrf2 a poor prognostic marker and presents inhibition as promising despite limited clinical evidence and acknowledged context-dependent effects.

↳ Conclusion; Nrf2 function subsection, pages 6–7

Does this match your read? Add your assessment ↓

Nabu Commentary

Table 1 and the subtype sections provide a broad map of preclinical Nrf2 findings across major leukemia categories. The structure is clear, but the article mainly catalogs individual studies rather than critically comparing their designs, heterogeneity, and boundary conditions. The absence of a source-selection method and the limited treatment of contrary AML findings reduce confidence in the balance of the synthesis. Consequently, claims about prognosis and therapeutic targeting require stronger qualification than the Abstract and Conclusion provide.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.6±0.2

Contribution
2.5

The review provides a useful leukemia-specific compilation and an Nrf2–NF-κB organizing frame, but its advance is primarily descriptive. The claim that Nrf2 is a poor prognostic marker in leukemia exceeds the clinical prognostic evidence described in the review.

Conclusion; Table 1; Nrf2 in leukemia subsection

“Nrf2 is a poor prognostic marker in leukemia”

Methodological Rigour
2.4

The subtype structure and study-level descriptions make the literature easy to survey, but the synthesis largely proceeds study by study. Conflicting AML findings receive little analysis, and no search or selection procedure explains how the literature was assembled.

Nrf2 and Acute myeloid leukemia subsection, page 16; entire manuscript

“However, a few conflicting studies suggest that increasing Nrf2 expression is influential in treating AML.”

Reporting
3.0

Headings and progression from molecular biology to leukemia subtypes make the review followable. Some Abstract and Conclusion statements are more definitive than the predominantly preclinical and context-dependent evidence warrants.

Abstract; Nrf2 function subsection, pages 6–7; Conclusion

“targeting Nrf2 combined with chemotherapy would be a therapeutic approach for leukemia treatment”

Positioning
2.8

The manuscript cites a broad Nrf2 literature and explicitly recognizes its tumor-suppressive and oncogenic roles. It does not trace acknowledged contrary AML findings through to the certainty of its concluding therapeutic recommendation.

Nrf2 function subsection, pages 6–7; Nrf2 and Acute myeloid leukemia subsection, page 16; Conclusion

“Therefore, more investigation is needed to clarify the role of Nrf2 in AML.”

Reliability

Caveats4 of 4 checks


Internal CoherenceNoted

The narrative is structurally coherent and contains no primary-data inconsistencies, but central wording in the Abstract and Conclusion is more definitive than the preclinical and context-dependent synthesis supports.

Research ConductClean

Ethics, consent, and data availability are appropriately marked not applicable for a narrative review, and no original-data or image-integrity issue was identified. A competing-interests statement was not visible in the supplied text, which is an assessability gap rather than evidence of misconduct.

Flags: 1 declared / 5 total

Reference IntegrityClean

217 of 218 checkable references verified

221 references in manuscript 3 have no canonical index record — counted, but not index-checkable 1 reference confirmed by manual review

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Cancer and neoplasms · Leukemia
Type of advanceSynthesis
Route to useSuggested
AdvanceConsolidates
BeneficiariesLarge
CitationsFWCI 2.9
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessControlled
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

Evidence for Nrf2-mediated chemotherapy resistance comes from controlled in vitro cell lines and xenograft mouse models, with no human clinical trials.

From the paper
“targeting Nrf2 combined with chemotherapy would be a therapeutic approach for leukemia treatment”

The paper names a therapeutic use for leukemia treatment but does not specify a profession or organisation that would implement it.

Pathway

Oncologists and hematologists could combine Nrf2 inhibitors with standard chemotherapy to overcome drug resistance in leukemia patients.

Barrier

No Nrf2 inhibitors have been tested in human leukemia clinical trials, and the paper notes finding inhibitors with right potency, specificity, and safety remains a significant challenge.

Evaluated 12 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Personalized redox medicine in inflammatory bowel diseases: an emerging role for HIF-1α and NRF2 as therapeutic targets

    Arno R. Bourgonje, Damian Klóska, Anna Grochot‐Przeczek, et al. · 2023 · Clinical medicine

    Evidence Score
    3.4±0.2
    Reliability
    No concerns
  2. A Protective Role of the NRF2-Keap1 Pathway in Maintaining Intestinal Barrier Function

    Zhiyong Wen, Weihua Liu, Xing Li, et al. · 2019 · Basic medicine

    Primary claim

    NRF2 reduced intestinal mucosal injury by suppressing oxidative stress

    Supported
    Evidence Score
    2.6±0.2
    Reliability
    Caveats
  3. The NRF2/Keap1 pathway as a therapeutic target in inflammatory bowel disease

    Sem Geertsema, Arno R. Bourgonje, Raphael R. Fagundes, et al. · 2023 · Clinical medicine

    Primary claim

    Preclinical evidence supports targeted therapeutic modulation of the NRF2/Keap1 pathway in the gastrointestinal tract, albeit human evidence is scarce.

    Tentative
    Evidence Score
    3.1±0.2
    Reliability
    No concerns

How the rubric works →